×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Chugai Pharmaceutical First Quarter 2024 Earnings: Misses Expectations
Simply Wall St
Chugai Pharmaceutical ( TSE:4519 ) First Quarter 2024 Results Key Financial Results Revenue: JP¥236.9b (down 24% from...
23 hours ago
Chugai's Value Creation Model | About Chugai | CHUGAI PHARMACEUTICAL CO., LTD.
中外製薬株式会社
Chugai's Value Creation Model ... Chugai has adopted “creating shared value” as its basic management policy, in line with the philosophy of growing together with...
4 months ago
Celiac Disease Pipeline Analysis 2024: Clinical Trials, FDA Approvals, Emerging Therapies, ROA, MOA and Treatment ...
Barchart.com
"Celiac Disease Pipeline"As per DelveInsight's assessment, globally, Celiac Disease pipeline constitutes 25+ key companies continuously...
2 days ago
Clinical Trials Arena Excellence Awards 2023: Chugai Pharmaceutical
Clinical Trials Arena
Chugai Pharmaceutical is a Category Award Winner in Research and Development, Product Launches, and Marketing in the 2023 Clinical Trials Arena Excellence...
2 months ago
Roche/Chugai's Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Scrip
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6...
3 weeks ago
Roche’s IL-6 Blocker Clears Phase III Bar, Still Falls Short of Expectations
BioSpace
Despite meeting its primary endpoint in a late-stage generalized myasthenia gravis trial, Roche and Chugai Pharmaceutical's Enspryng did not...
1 month ago
Chugai Earnings: Slight Outperformance, Healthy Pipeline Progress, Shares Near Fair Value Estimate
Morningstar
Narrow-moat Chugai's 4519 third-quarter earnings were slightly better than expectations on strong overseas shipments of Hemlibra to Roche,...
5 months ago
China is the first to approve Roche's PNH drug crovalimab
Fierce Pharma
China has become the first country to sign off on Roche's PNH drug crovalimab, a subcutaneous answer to AZ's infused treatments Soliris and...
2 months ago
Biotech Stocks Argenx, Immunovant Soar On Chugai's Lackluster Results In Myasthenia Gravis
Investor's Business Daily
Biotech stocks Argenx and Immunovant surged Thursday — and Tourmaline fell — on a rival's lackluster muscle disease drug study.
1 month ago
Satralizumab Fails to Reach Expected Clinical Benefit in LUMINESCE Study of Myasthenia Gravis
Neurology live
According to an update from Chugai Pharmaceutical, the company's genetical recombination of satralizumab (Enspryng) demonstrated...
1 month ago